SG10201809066TA - 5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor Agonists - Google Patents
5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor AgonistsInfo
- Publication number
- SG10201809066TA SG10201809066TA SG10201809066TA SG10201809066TA SG10201809066TA SG 10201809066T A SG10201809066T A SG 10201809066TA SG 10201809066T A SG10201809066T A SG 10201809066TA SG 10201809066T A SG10201809066T A SG 10201809066TA SG 10201809066T A SG10201809066T A SG 10201809066TA
- Authority
- SG
- Singapore
- Prior art keywords
- carboxamides
- disubstituted
- pyridine
- receptor agonists
- cannabinoid receptor
- Prior art date
Links
- 229940121376 cannabinoid receptor agonist Drugs 0.000 title abstract 3
- 239000003537 cannabinoid receptor agonist Substances 0.000 title abstract 3
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title abstract 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003222 pyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163555 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201809066TA true SG10201809066TA (en) | 2018-11-29 |
Family
ID=50424143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608108SA SG11201608108SA (en) | 2014-04-04 | 2015-04-01 | Pyridine-2-amides useful as cb2 agonists |
| SG10201809066TA SG10201809066TA (en) | 2014-04-04 | 2015-04-01 | 5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor Agonists |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608108SA SG11201608108SA (en) | 2014-04-04 | 2015-04-01 | Pyridine-2-amides useful as cb2 agonists |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20160376262A1 (enExample) |
| EP (1) | EP3126359A1 (enExample) |
| JP (1) | JP6654574B2 (enExample) |
| KR (1) | KR20160142365A (enExample) |
| CN (1) | CN106132958A (enExample) |
| AR (1) | AR099933A1 (enExample) |
| AU (1) | AU2015239539A1 (enExample) |
| CA (1) | CA2943013A1 (enExample) |
| CL (1) | CL2016002483A1 (enExample) |
| CR (1) | CR20160448A (enExample) |
| EA (1) | EA030116B1 (enExample) |
| IL (1) | IL247817A0 (enExample) |
| MA (1) | MA39843A (enExample) |
| MX (1) | MX2016012689A (enExample) |
| PE (1) | PE20161370A1 (enExample) |
| PH (1) | PH12016501865A1 (enExample) |
| SG (2) | SG11201608108SA (enExample) |
| TW (1) | TW201623276A (enExample) |
| WO (1) | WO2015150440A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507994QA (en) | 2013-03-26 | 2015-10-29 | Hoffmann La Roche | Novel pyridine derivatives |
| EP3126354B1 (en) | 2014-04-04 | 2020-01-22 | H. Lundbeck A/S | Halogenated quinazolin-thf-amines as pde1 inhibitors |
| HRP20200606T1 (hr) | 2015-12-09 | 2020-07-10 | F. Hoffmann - La Roche Ag | Derivati fenila kao agonisti kanabinoidnog receptora 2 |
| TW201808906A (zh) | 2016-03-16 | 2018-03-16 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代吡啶化合物 |
| WO2018234284A1 (en) | 2017-06-20 | 2018-12-27 | F. Hoffmann-La Roche Ag | Pyridine derivatives |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| SG11202009103WA (en) * | 2018-06-27 | 2020-10-29 | Hoffmann La Roche | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| CN112074513B (zh) * | 2018-06-27 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 作为优先大麻素2激动剂的吡啶和吡嗪衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1863778B1 (en) | 2005-03-31 | 2015-12-30 | Merck Sharp & Dohme Corp. | Spirocyclic thrombin receptor antagonists |
| FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
| CN101855222A (zh) * | 2007-05-10 | 2010-10-06 | 通用电气健康护理有限公司 | 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物 |
| EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| ES2643058T3 (es) * | 2012-12-07 | 2017-11-21 | F. Hoffmann-La Roche Ag | Piridina-2-amidas útiles como agonistas de CB2 |
| CA2885418A1 (en) * | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Novel pyrazine derivatives as cb2 receptor agonists |
-
2015
- 2015-04-01 SG SG11201608108SA patent/SG11201608108SA/en unknown
- 2015-04-01 CN CN201580017199.1A patent/CN106132958A/zh active Pending
- 2015-04-01 AR ARP150100985A patent/AR099933A1/es unknown
- 2015-04-01 MA MA039843A patent/MA39843A/fr unknown
- 2015-04-01 CR CR20160448A patent/CR20160448A/es unknown
- 2015-04-01 EA EA201691983A patent/EA030116B1/ru not_active IP Right Cessation
- 2015-04-01 AU AU2015239539A patent/AU2015239539A1/en not_active Abandoned
- 2015-04-01 KR KR1020167030780A patent/KR20160142365A/ko not_active Withdrawn
- 2015-04-01 WO PCT/EP2015/057151 patent/WO2015150440A1/en not_active Ceased
- 2015-04-01 PE PE2016001656A patent/PE20161370A1/es unknown
- 2015-04-01 SG SG10201809066TA patent/SG10201809066TA/en unknown
- 2015-04-01 CA CA2943013A patent/CA2943013A1/en not_active Abandoned
- 2015-04-01 EP EP15713492.5A patent/EP3126359A1/en not_active Withdrawn
- 2015-04-01 MX MX2016012689A patent/MX2016012689A/es unknown
- 2015-04-01 JP JP2016560674A patent/JP6654574B2/ja not_active Expired - Fee Related
- 2015-04-02 TW TW104111026A patent/TW201623276A/zh unknown
-
2016
- 2016-09-09 US US15/260,826 patent/US20160376262A1/en not_active Abandoned
- 2016-09-14 IL IL247817A patent/IL247817A0/en unknown
- 2016-09-22 PH PH12016501865A patent/PH12016501865A1/en unknown
- 2016-09-30 CL CL2016002483A patent/CL2016002483A1/es unknown
-
2018
- 2018-07-24 US US16/044,320 patent/US20180327396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015239539A1 (en) | 2016-09-29 |
| CA2943013A1 (en) | 2015-10-08 |
| JP6654574B2 (ja) | 2020-02-26 |
| TW201623276A (zh) | 2016-07-01 |
| IL247817A0 (en) | 2016-11-30 |
| EP3126359A1 (en) | 2017-02-08 |
| CL2016002483A1 (es) | 2017-03-10 |
| MA39843A (fr) | 2017-02-08 |
| PH12016501865A1 (en) | 2016-12-19 |
| US20180327396A1 (en) | 2018-11-15 |
| CN106132958A (zh) | 2016-11-16 |
| EA201691983A1 (ru) | 2017-01-30 |
| SG11201608108SA (en) | 2016-10-28 |
| MX2016012689A (es) | 2016-12-14 |
| EA030116B1 (ru) | 2018-06-29 |
| JP2017509676A (ja) | 2017-04-06 |
| CR20160448A (es) | 2016-12-14 |
| WO2015150440A1 (en) | 2015-10-08 |
| AR099933A1 (es) | 2016-08-31 |
| KR20160142365A (ko) | 2016-12-12 |
| US20160376262A1 (en) | 2016-12-29 |
| PE20161370A1 (es) | 2016-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201809066TA (en) | 5,6-Disubstituted Pyridine-2-Carboxamides and 5,6-Disubstituted Pyrazine-2-Carboxamides as Cannabinoid Receptor Agonists | |
| PH12017502393A1 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| PH12015501073A1 (en) | Novel pyridine derivatives | |
| MX365494B (es) | Procedimiento de compuesto antifungico. | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| PH12016501849A1 (en) | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | |
| PH12018501181A1 (en) | Phenyl derivatives as cannabinoid receptor 2 agonists | |
| PH12015501933B1 (en) | Novel pyridine derivatives | |
| MX355354B (es) | Derivados aminopirimidinicos 4,6-disustituidos novedosos. | |
| MX2016012053A (es) | Procedimiento de compuesto antifungico. | |
| MA40583A (fr) | Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation | |
| PH12018501979B1 (en) | Aminothiazole derivatives useful as antiviral agents | |
| UA116801C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 | |
| MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| TN2016000490A1 (en) | Naphthyridinedione derivatives. | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| MX2017002015A (es) | Ligando del receptor 2 de canabinoide radiomarcado. | |
| MX2016004393A (es) | Derivados de carboxamida como compuestos pesticidas. | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| MX2015016766A (es) | Nuevos derivados de tetrazolona. | |
| WO2014172363A3 (en) | Combretastatin analogs | |
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. |